Stock Track | Summit Therapeutics Soars on Bullish Analyst Coverage

Stock Track

2024/11/04

Shares of Summit Therapeutics PLC (SMMT) soared 5.06% on November 4th after JMP Securities initiated coverage on the biopharmaceutical company with a "Market Outperform" rating.

JMP Securities analyst Peter Ganzer set a price target of $32 for SMMT stock, reflecting significant upside from current levels. Ganzer cited Summit's promising pipeline of antibiotics and other anti-infective treatments in his bullish initiation.

The positive analyst coverage acted as a catalyst for SMMT shares, which jumped as investors reacted to the optimistic outlook from JMP Securities. With the significant price target, the market appears to be anticipating further upside potential for Summit Therapeutics in the coming months.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1106746439"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106746439\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106746439?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-04 23:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106746439","market":"us","top_or_hot":-1,"title":"Stock Track | Summit Therapeutics Soars on Bullish Analyst Coverage","media":"Stock Track","content":"<p>Shares of Summit Therapeutics PLC (SMMT) soared 5.06% on November 4th after JMP Securities initiated coverage on the biopharmaceutical company with a \"Market Outperform\" rating.</p>\n\n<p>JMP Securities analyst Peter Ganzer set a price target of $32 for SMMT stock, reflecting significant upside from current levels. Ganzer cited Summit's promising pipeline of antibiotics and other anti-infective treatments in his bullish initiation.</p>\n\n<p>The positive analyst coverage acted as a catalyst for SMMT shares, which jumped as investors reacted to the optimistic outlook from JMP Securities. With the significant price target, the market appears to be anticipating further upside potential for Summit Therapeutics in the coming months.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Summit Therapeutics Soars on Bullish Analyst Coverage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Summit Therapeutics Soars on Bullish Analyst Coverage\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-11-04 23:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Summit Therapeutics PLC (SMMT) soared 5.06% on November 4th after JMP Securities initiated coverage on the biopharmaceutical company with a \"Market Outperform\" rating.</p>\n\n<p>JMP Securities analyst Peter Ganzer set a price target of $32 for SMMT stock, reflecting significant upside from current levels. Ganzer cited Summit's promising pipeline of antibiotics and other anti-infective treatments in his bullish initiation.</p>\n\n<p>The positive analyst coverage acted as a catalyst for SMMT shares, which jumped as investors reacted to the optimistic outlook from JMP Securities. With the significant price target, the market appears to be anticipating further upside potential for Summit Therapeutics in the coming months.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"","article_id":"1106746439","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106746439","pubTimestamp":1730735192,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Summit Therapeutics PLC  soared 5.06% on November 4th after JMP Securities initiated coverage on the biopharmaceutical company with a \"Market Outperform\" rating.JMP Securities analyst Peter Ganzer set a price target of $32 for SMMT stock, reflecting significant upside from current levels. Ganzer cited Summit's promising pipeline of antibiotics and other anti-infective treatments in his bullish initiation.The positive analyst coverage acted as a catalyst for SMMT shares, which jumped as","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMMT":"Summit Therapeutics PLC"},"translate_title":"分析师看涨报道导致Summit Therapeutics股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1},"content_text":"Shares of Summit Therapeutics PLC (SMMT) soared 5.06% on November 4th after JMP Securities initiated coverage on the biopharmaceutical company with a \"Market Outperform\" rating.\nJMP Securities analyst Peter Ganzer set a price target of $32 for SMMT stock, reflecting significant upside from current levels. Ganzer cited Summit's promising pipeline of antibiotics and other anti-infective treatments in his bullish initiation.\nThe positive analyst coverage acted as a catalyst for SMMT shares, which jumped as investors reacted to the optimistic outlook from JMP Securities. With the significant price target, the market appears to be anticipating further upside potential for Summit Therapeutics in the coming months.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}